The company also predicted a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth even as prices remain under pressure.
"We think that given the concerns around margins going into results, we think this result/guide is good," Barclays analyst Emily Field said, noting the earnings guidance was at the higher end of her expectations. Sales of its best-selling cancer drugs - Tagrisso, Imfinzi and Lynparza - came in just below estimates from Cowen analysts.
shares have outperformed rivals in recent years, gaining 41% since January 2020 due to its success in oncology.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: